Adamis Pharmaceuticals Corporation
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ebrahim Versi
- Full Time Employees
- 11
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 11682 El Camino Real San Diego CA United States of America 92130
- IPO Date
- Aug 14, 1995
- CIK
- 0000887247
- Website
- adamispharmaceuticals.com
- Similar Companies
- Business
- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a commercial-stage biopharmaceutical company founded in 2006 and headquartered in San Diego, California, develops and commercializes specialty pharmaceutical products primarily targeting allergy, respiratory disease, opioid overdose, and opioid use disorder; its FDA-approved commercial offerings include SYMJEPI (epinephrine) injection in 0.15 mg and 0.3 mg doses for emergency treatment of anaphylaxis in patients weighing 33 pounds or more, and ZIMHI (naloxone) injection for opioid overdose reversal; following its 2023 merger with DMK Pharmaceuticals, the company advances a pipeline of novel neuropeptide analogues including lead candidate DPI-125 for opioid use disorder and pain management, DPI-221 for bladder control, and DPI-289 for advanced Parkinson's disease, while previously operating a compounding pharmacy through US Compounding Inc. subsidiary sold in assets for approximately $10-20 million in 2021. The company conducts operations principally in the United States, serving patients, physicians, hospitals, and clinics through its approved injectable therapies and development-stage neuro-based treatments. Recent financing includes an $8.0 million public offering closed in August 2023 and a prior March 2023 registered direct offering raising gross proceeds through common stock and warrants.
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert
Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder
Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
Adamis Pharmaceuticals Announces Reverse Stock Split
Adamis Pharmaceuticals Corporation (ADMP) Q1 2023 Earnings Call Transcript
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Adamis Pharmaceuticals Corporation (ADMP) Q4 2022 Earnings Call Transcript
Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering
ADAMIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adamis Pharmaceuticals Corporation - ADMP
SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Adamis Pharmaceuticals Corp. - ADMP
Adamis Pharmaceuticals (ADMP) Stock Wavers on Merger News
ADMP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Adamis Pharmaceuticals Corporation Is Fair to Shareholders
Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger